Abstract
Objective We described the patterns of chemotherapy use and outcomes in patients diagnosed with stage III or IV non-small cell lung cancer (NSCLC) in England.
Method In this retrospective population-based study, we included 20,716 (62% stage IV) patients with NSCLC diagnosed in 2014-17 treated with chemotherapy. We used the Systemic Anti-Cancer Treatment (SACT) dataset to describe changes in treatment plan and estimated 30 and 90-day mortality rates and median, 6- and 12-month overall survival (OS) using Kaplan Meier estimator for patients aged <75 and ≥ 75 by stage. Using flexible hazard regression models we assessed the impact of age, stage, treatment intent (stage III) and performance status on survival.
Results Patients aged ≥ 75 years were less likely to receive 2 or more regimens, more likely to have their treatment modified because of comorbidities and their doses reduced compared to younger patients. However, early mortality rates and overall survival were similar across ages, apart from the oldest patients with stage III disease.
Conclusion This observational study demonstrates that age is associated with treatment choices in an older population with advanced NSCLC in England. Although this reflecting a pre-immunotherapy period, given the median age of NSCLC patients and increasingly older population, these results suggest older patients (>75yrs) may need additional support to access more intense treatments that may influence overall survival.
Competing Interest Statement
SP, EJAM and DD declare no conflict of interest. KNF reports the following: Active research funding/grant: Avoiding cardiac toxicity in lung cancer cases treated with curative-intent radiotherapy to improve survival. Co-chief investigator (with Prof Faivre-Finn). Funder Yorkshire Cancer Research (YCR) PREHABS: Prehabilitation, Radiotherapy Exercise, smoking Habit cessation and Balanced diet Study. Co-chief investigator with Dr Carole Burnett. Funder Yorkshire Cancer Research (YCR) CONCOrDE- Study Arm Lead in platform trial of DNA-damage repair inhibitors with radical radiotherapy in stage III NSCLC. (CRUK/AstraZenaca joint funding) Yorkshire Lung Screening Trial Biomarker Trial- Co-investigator and PI for Biomarker sub-study of main trial. Funder Yorkshire Cancer Research (YCR) UK PI for AstraZeneca PACIFIC-4 Study (currently off license) and CI for AstraZeneca CODAK study Honoraria/Advisory Boards: AstraZeneca, Amgen, Boehringer-Ingelheim, Bristol-Meyers-Squibb, Lilly, Roche and Takeda Educational support: AstraZeneca, Boehringer-Ingelheim, ELEKTA, Pierre Fabre, Novartis, Roche and Takeda.
Funding Statement
SP was supported by the European Union s Horizon 2020 Research and Innovation Programme, Belgium under the Marie Skłodowska-Curie grant agreement No 842817. DD is supported by Cancer Research UK (grant no C8225/A21133). Funders had no involvement in the present study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
North of Scotland Research Ethics Service gave ethical approval for this work (REC 19 NS 0057).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Twitter handles: @SPilleron, @EJAMorris
Following Reviewer's comment and confirmation from KNF, a co-author and clinician, chemotherapy intent for patients with stage IV NSCLC previously coded as "curative" was coded as "palliative". Some results were modified accordingly. One paragraph at the end of the discussion was added. Some minor edits were made.
Data Availability
De-personalised study data may be made available on request to accredited researchers who submit a proposal that is approved by the PHE Office for Data Release.
List of abbreviations
- NSCLC
- Non-small cell lung cancer;
- OS
- overall survival;
- SACT
- Systemic Anti-Cancer treatment
